Welcome to our dedicated page for ADC Therapeutics SA news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on ADC Therapeutics SA stock.
ADC Therapeutics SA (NYSE: ADCT) is a commercial-stage biotechnology company headquartered in Lausanne, Vaud, Switzerland. The company specializes in the development of antibody-drug conjugates (ADCs) to treat hematological malignancies and solid tumors. ADC Therapeutics is particularly known for its product ZYNLONTA® (loncastuximab tesirine-lpyl), which received accelerated approval from the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. ZYNLONTA is also under development for use in combination with other agents and for earlier lines of therapy.
The company has a broad portfolio of ADCs in various stages of clinical and preclinical development, including camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701, and ADCT-212. ADC Therapeutics leverages its proprietary technology to improve the treatment outcomes for cancer patients, focusing on both hematologic cancers and solid tumors.
In recent news, ADC Therapeutics announced several key updates, including the completion of dose escalation in their LOTIS-7 trial, which is evaluating ZYNLONTA in combination with bispecific antibodies for heavily pre-treated patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The company also presented promising data from a Phase 2 trial evaluating ZYNLONTA in patients with relapsed/refractory marginal zone lymphoma, showing high response rates and a good safety profile.
Financially, ADC Therapeutics reported ZYNLONTA net sales of $17.8 million for the first quarter of 2024 and continues to advance its hematology and solid tumor pipelines. The company has operations in London, the San Francisco Bay Area, and New Jersey. For more information, visit adctherapeutics.com and follow the company on LinkedIn.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 17,900 common shares to four new employees on September 3, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This move aligns with NYSE's Listed Company Manual Rule 303A.08, demonstrating ADC Therapeutics' commitment to incentivizing high performance and long-term success.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September. The company will be represented by CEO Ameet Mallik at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring a virtual fireside chat at 7:00 a.m. ET.
2. 10th Cantor Global Healthcare Conference 2024 on September 18, 2024, with a fireside chat scheduled from 11:30-12:00 p.m. ET.
Live webcasts of both presentations will be accessible through the company's website, with replays available for approximately 30 days after each event.
ADC Therapeutics reported Q2 2024 financial results and operational updates. ZYNLONTA achieved commercial profitability in H1 2024, with net sales of $17.0 million in Q2. The LOTIS-7 trial is progressing, with efficacy and safety data expected by year-end 2024. LOTIS-5 trial enrollment is expected to complete before year-end 2024. The company's cash position of $300.1 million is expected to extend runway into mid-2026.
Financial highlights include:
- Net product revenues of $34.9 million for H1 2024
- R&D expense decreased to $50.0 million for H1 2024
- Net loss of $83.2 million, or $0.93 per share for H1 2024
- Adjusted net loss of $55.5 million, or $0.62 per share for H1 2024
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 38,600 common shares to three new employees on August 1, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This action aligns with NYSE's Listed Company Manual Rule 303A.08 for employment inducement exemptions.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced a conference call and live webcast scheduled for August 6, 2024, at 8:30 a.m. EDT. The event will cover the company's second quarter 2024 financial results and provide operational updates. Interested parties can register for the call to receive dial-in details and a unique PIN. A live webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the event.
ADC Therapeutics SA (NYSE: ADCT) announced the issuance of stock options totaling 172,400 common shares to six new employees on July 1, 2024. These grants are part of an inducement plan to attract and retain talent, approved by the company's Board's Compensation Committee.
The grants are structured to vest 25% on the first anniversary of the grant date, with the remaining shares vesting monthly over the following three years, contingent on continued employment. This initiative is in compliance with NYSE Rule 303A.08.
ADC Therapeutics (NYSE: ADCT) will join the Russell 2000® and Russell 3000® indexes effective July 1, 2024. This inclusion follows the 2024 Russell US Indexes annual reconstitution, capturing the 4,000 largest US stocks as of April 30, 2024, based on market capitalization. CEO Ameet Mallik stated that this milestone validates ADC Therapeutics' corporate and capital allocation strategy, and highlights progress in their hematology and solid tumor portfolios. The Russell indexes, managed by FTSE Russell, are benchmarks for about $10.5 trillion in assets and guide investment strategies for many institutional investors. Membership in the Russell 3000® ensures automatic inclusion in either the Russell 1000® or Russell 2000® indexes.
ADC Therapeutics (NYSE: ADCT) has announced the issuance of stock options to three new employees as part of its Inducement Plan. A total of 109,800 options were granted on June 3, 2024, to motivate and reward the new hires. These grants were approved by the Compensation Committee of the Board of Directors and made under the NYSE's Rule 303A.08 exemption. The options vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, contingent on continued employment.
ADC Therapeutics announced that CEO Ameet Mallik will present a company overview at the Jefferies Global Healthcare Conference on June 6, 2024, at 11:30 a.m. ET.
The presentation will be webcast live and available on the company's investor relations website, with a replay accessible for about 30 days.
ADC Therapeutics (NYSE: ADCT) announced that CEO Ameet Mallik will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for Monday, May 20, 2024, at 2:00 p.m. ET. The presentation will be webcast live and available for replay for approximately 30 days on the company's investor website.
FAQ
What is the current stock price of ADC Therapeutics SA (ADCT)?
What is the market cap of ADC Therapeutics SA (ADCT)?
What is the primary focus of ADC Therapeutics?
What is ZYNLONTA?
Where is ADC Therapeutics headquartered?
What recent developments has ADC Therapeutics announced?
What are some of the product candidates in ADC Therapeutics' pipeline?
How did ZYNLONTA perform financially in the first quarter of 2024?
Does ADC Therapeutics have international operations?
What are the strategic goals of ADC Therapeutics?
How can I learn more about ADC Therapeutics?
Who is the current Chief Executive Officer of ADC Therapeutics?
